Diprenorphine

	WikiDoc Resources for Diprenorphine
Articles
Most recent articles on Diprenorphine Most cited articles on Diprenorphine Review articles on Diprenorphine Articles on Diprenorphine in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Diprenorphine Images of Diprenorphine Photos of Diprenorphine Podcasts & MP3s on Diprenorphine Videos on Diprenorphine
Evidence Based Medicine
Cochrane Collaboration on Diprenorphine Bandolier on Diprenorphine TRIP on Diprenorphine
Clinical Trials
Ongoing Trials on Diprenorphine at Clinical Trials.gov Trial results on Diprenorphine Clinical Trials on Diprenorphine at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Diprenorphine NICE Guidance on Diprenorphine NHS PRODIGY Guidance FDA on Diprenorphine CDC on Diprenorphine
Books
Books on Diprenorphine
News
Diprenorphine in the news Be alerted to news on Diprenorphine News trends on Diprenorphine
Commentary
Blogs on Diprenorphine
Definitions
Definitions of Diprenorphine
Patient Resources / Community
Patient resources on Diprenorphine Discussion groups on Diprenorphine Patient Handouts on Diprenorphine Directions to Hospitals Treating Diprenorphine Risk calculators and risk factors for Diprenorphine
Healthcare Provider Resources
Symptoms of Diprenorphine Causes & Risk Factors for Diprenorphine Diagnostic studies for Diprenorphine Treatment of Diprenorphine
Continuing Medical Education (CME)
CME Programs on Diprenorphine
International
Diprenorphine en Espanol Diprenorphine en Francais
Business
Diprenorphine in the Marketplace Patents on Diprenorphine
Experimental / Informatics
List of terms related to Diprenorphine

Diprenorphine
Identifiers
	IUPAC name (5α,7α)-17-(Cyclopropylmethyl) -4,5-epoxy-18,19-dihydro-3-hydroxy-6-methoxy -α,α-dimethyl-6,14-ethenomorphinan-7-methanol;
CAS Number	14357-78-9;
PubChem CID	443408;
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Formula	C26H35NO4
Molar mass	425.56 g/mol
3D model (JSmol)	Interactive image;
	SMILES CC(C)([C@H]1C[C@@]23CC[C@@]1([C@H]4[C@@]25CCN([C@@H]3CC6=C5C(=C(C=C6)O)O4)CC7CC7)OC)O;

Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [1] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

Diprenorphine (Revivon, M5050) is an opiate antagonist^[1] used to reverse the effects of the super-potent opioid analgesics such as etorphine and carfentanil that are used for tranquilizing large animals in veterinary medicine.

Diprenorphine is the strongest opiate antagonist that is commercially available (some 100 times more potent as an antagonist than nalorphine),^[2] and is used for reversing the effects of very strong opioids for which the binding affinity is so high that naloxone does not effectively or reliably reverse the narcotic effects.^[3] These super-potent opioids are not used in humans because the dose for a human is so small that it would be difficult to measure properly, so there is an excessive risk of overdose leading to fatal respiratory depression. However conventional opioid derivatives are not strong enough to rapidly tranquilize large animals such as elephants and rhinos, so drugs such as etorphine or carfentanil are available for this purpose.

Diprenorphine is considered the specific antagonist for etorphine and carfentanil,^[4] and is normally used to remobilise animals once veterinary procedures have been completed,^[5] however it may also be used on humans in the event that they are accidentally exposed to etorphine or carfentanil, for instance if someone working with large animals suffered a needlestick injury with a dart from a tranquiliser dart gun that was loaded with etorphine or carfentanil, they would be given diprenorphine as an antidote.

In theory diprenorphine could also be used as an antidote for treating overdose of certain opioid derivatives which are used in humans, such as buprenorphine, for which the binding affinity is so high that naloxone does not reliably reverse the narcotic effects. However diprenorphine is not generally available in hospitals, instead a vial of diprenorphine is supplied with the etorphine or carfentanil specifically for reversing the effects of these drugs, so use of diprenorphine for treating buprenorphine overdose is not carried out in practice although it would work in theory.

References

↑ Lewis JW, Husbands SM. The orvinols and related opioids--high affinity ligands with diverse efficacy profiles. Current Pharmaceutical Design. 2004;10(7):717-32.
↑ Furst S, Hosztafi S, Friedmann T. Structure-Activity Relationships of Synthetic and Semisynthetic Opioid Agonists and Antagonists. Current Medicinal Chemistry, 1995; 1(6):423-440. ISSN:0929-8673
↑ Takemori AE, Hayashi G, Smits SE. Studies on the quantitative antagonism of analgesics by naloxone and diprenorphine. European Journal of Pharmacology. 1972 Oct;20(1):85-92.
↑ Jessup DA, Clark WE, Jones KR, Clark R, Lance WR. Immobilization of free-ranging desert bighorn sheep, tule elk, and wild horses, using carfentanil and xylazine: reversal with naloxone, diprenorphine, and yohimbine. Journal of the American Veterinary Medical Association. 1985 Dec 1;187(11):1253-4.
↑ Alford BT, Burkhart RL, Johnson WP. Etorphine and diprenorphine as immobilizing and reversing agents in captive and free-ranging mammals. Journal of the American Veterinary Medical Association. 1974 Apr 1;164(7):702-5.

Template:Opioids Template:SIB

Template:WH Template:WS

[1] Lewis JW, Husbands SM. The orvinols and related opioids--high affinity ligands with diverse efficacy profiles. Current Pharmaceutical Design. 2004;10(7):717-32.

[2] Furst S, Hosztafi S, Friedmann T. Structure-Activity Relationships of Synthetic and Semisynthetic Opioid Agonists and Antagonists. Current Medicinal Chemistry, 1995; 1(6):423-440. ISSN:0929-8673

[3] Takemori AE, Hayashi G, Smits SE. Studies on the quantitative antagonism of analgesics by naloxone and diprenorphine. European Journal of Pharmacology. 1972 Oct;20(1):85-92.

[4] Jessup DA, Clark WE, Jones KR, Clark R, Lance WR. Immobilization of free-ranging desert bighorn sheep, tule elk, and wild horses, using carfentanil and xylazine: reversal with naloxone, diprenorphine, and yohimbine. Journal of the American Veterinary Medical Association. 1985 Dec 1;187(11):1253-4.

[5] Alford BT, Burkhart RL, Johnson WP. Etorphine and diprenorphine as immobilizing and reversing agents in captive and free-ranging mammals. Journal of the American Veterinary Medical Association. 1974 Apr 1;164(7):702-5.

[1]

[2]

[3]

[4]

[5]

Identifiers

IUPAC name (5α,7α)-17-(Cyclopropylmethyl) -4,5-epoxy-18,19-dihydro-3-hydroxy-6-methoxy -α,α-dimethyl-6,14-ethenomorphinan-7-methanol
CAS Number	14357-78-9
PubChem CID	443408
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Formula	C₂₆H₃₅NO₄
Molar mass	425.56 g/mol
3D model (JSmol)	Interactive image
SMILES CC(C)([C@H]1C[C@@]23CC[C@@]1([C@H]4[C@@]25CCN([C@@H]3CC6=C5C(=C(C=C6)O)O4)CC7CC7)OC)O

Diprenorphine

References

Navigation menu

Search